Holen Sie sich die Stockscreener-App
8.20
4.86%
0.38
Handel nachbörslich:
8.20
Schlusskurs vom Vortag:
$7.82
Offen:
$7.92
24-Stunden-Volumen:
737.64K
Relative Volume:
0.53
Marktkapitalisierung:
$731.17M
Einnahmen:
$380.79M
Nettoeinkommen (Verlust:
$49.27M
KGV:
11.71
EPS:
0.7
Netto-Cashflow:
$10.68M
1W Leistung:
+0.24%
1M Leistung:
+6.77%
6M Leistung:
+132.29%
1J Leistung:
+314.14%
1-Tages-Spanne:
$7.82
$8.31
1-Wochen-Bereich:
$7.48
$8.31
52-Wochen-Spanne:
$1.915
$8.72
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Firmenname
Amylyx Pharmaceuticals Inc
Sektor
Branche
Telefon
617-683-0917
Adresse
43 THORNDIKE STREET, CAMBRIDGE
Vergleichen Sie AMLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
8.20 | 681.24M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-06-24 | Eingeleitet | Guggenheim | Buy |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2025-05-30 | Eingeleitet | TD Cowen | Buy |
| 2025-04-07 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-11-18 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-03-18 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-11 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-24 | Hochstufung | Goldman | Neutral → Buy |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-01-05 | Eingeleitet | BofA Securities | Buy |
| 2022-05-25 | Eingeleitet | Citigroup | Buy |
| 2022-04-01 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
Will Amylyx Pharmaceuticals Inc. benefit from rising consumer demandTrend Confirmation Stock Picks - thegnnews.com
Amylyx Pharmaceuticals Advances ALS Treatment with AMX0114 Clinical Trial - MSN
Amylyx anticipates Avexitide Phase III data in H1 2026 while expanding rare disease pipeline - MSN
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2025 Earnings Call Transcript - Insider Monkey
Promising Market Potential and Financial Outlook for Amylyx Pharmaceuticals Inc. Driven by Avexitide’s Advancements - TipRanks
Amylyx Pharmaceuticals Q2 2025 Earnings Preview - MSN
Amylyx Pharmaceuticals: Progress in Trials and Financials - TipRanks
Amylyx Pharmaceuticals: Strategic Progress in Neurodegenerative Therapies and the Path to Long-Term Value - AInvest
Amylyx in 2026: A High-Risk, High-Reward Biotech Catalyst Play - AInvest
Progressive Supranuclear Palsy Market on Upward Trajectory During the Forecast Period (2025-2034) with Emerging Immunotherapies | DelveInsight - Yahoo Finance
Amylyx Pharmaceuticals' Q2 2025: Key Contradictions in PBH Patient Estimates, Trial Analysis, and Market Opportunities - AInvest
Amylyx Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Amylyx Pharmaceuticals’ Phase 3 Study on Avexitide: A Potential Game-Changer for Post-Bariatric Hypoglycemia - TipRanks
Promising Future for Amylyx Pharmaceuticals: Buy Rating Backed by Avexitide’s Market Potential - TipRanks
Amylyx (AMLX) Q2 Net Loss Narrows 43% - Nasdaq
Transcript : Amylyx Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results - BioSpace
Amylyx Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Amylyx Pharmaceuticals: A Biotech Undervalued by Momentum and Milestones - AInvest
Amylyx Pharmaceuticals Advances Avexitide Study for Post-Bariatric Hypoglycemia - TipRanks
Amylyx Pharmaceuticals’ ALS Study: A Potential Game-Changer for Investors - TipRanks
Amylyx Pharmaceuticals Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
After strategic reset, Amylyx downsizes, moves Cambridge HQ - The Business Journals
Watch for Bullish Crossover in Amylyx Pharmaceuticals Inc.High Return Stock Focus With Safety Emphasized - beatles.ru
How volatile is Amylyx Pharmaceuticals Inc. stock compared to the marketAchieve exceptional returns with expert guidance - Jammu Links News
What is the dividend policy of Amylyx Pharmaceuticals Inc. stockMaximize gains with proven stock analysis - Jammu Links News
What are analysts’ price targets for Amylyx Pharmaceuticals Inc. in the next 12 monthsSkyrocketing profit margins - Jammu Links News
What are the latest earnings results for Amylyx Pharmaceuticals Inc.Build wealth with long-term growth strategies - Jammu Links News
What analysts say about Amylyx Pharmaceuticals Inc. stockBuild a portfolio that delivers consistent profits - Jammu Links News
Should I hold or sell Amylyx Pharmaceuticals Inc. stock in 2025Fastest return on investment - Jammu Links News
What makes Amylyx Pharmaceuticals Inc. stock price move sharplyBuild wealth faster with consistent investment plans - Jammu Links News
What are Amylyx Pharmaceuticals Inc. company’s key revenue driversBreakthrough wealth creation - Jammu Links News
What catalysts could drive Amylyx Pharmaceuticals Inc. stock higher in 2025Discover high-impact stocks for growth - Jammu Links News
Amylyx Pharmaceuticals Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - Jammu Links News
What institutional investors are buying Amylyx Pharmaceuticals Inc. stockMaximize your gains with expert trading tips - Jammu Links News
When is Amylyx Pharmaceuticals Inc. stock expected to show significant growthUnlock exclusive stock market forecasts - Jammu Links News
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX): Is Breakeven Near? - 富途牛牛
How many analysts rate Amylyx Pharmaceuticals Inc. as a “Buy”Unlock expert insights for smarter investing - Jammu Links News
Does Amylyx Pharmaceuticals Inc. stock perform well during market downturnsTransform your portfolio with high-yield stocks - Jammu Links News
Is it the right time to buy Amylyx Pharmaceuticals Inc. stockTriple-digit return opportunities - Jammu Links News
In Rare Move, FDA Panel Gives Support to Controversial ALS Drug in Second Review - Physician's Weekly
What is the risk reward ratio of investing in Amylyx Pharmaceuticals Inc. stockChart Pattern Updates For Fast Growth - Jammu Links News
Why Amylyx Pharmaceuticals Inc. stock attracts strong analyst attentionTrend Reversal Signal Prediction Plan - beatles.ru
Amylyx Pharmaceuticals Inc. Rebound Backed by Sentiment ShiftVerified Signal From Chart Patterns Detected - metal.it
Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 - BioSpace
Amylyx Pharmaceuticals Announces Q2 2025 Earnings Call: Here's How to Join the Discussion - Stock Titan
Finanzdaten der Amylyx Pharmaceuticals Inc-Aktie (AMLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Amylyx Pharmaceuticals Inc-Aktie (AMLX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bedrosian Camille L | Chief Medical Officer |
Mar 31 '25 |
Sale |
3.47 |
12,425 |
43,082 |
194,375 |
| Mazzariello Gina | Chief Legal Officer |
Mar 31 '25 |
Sale |
3.48 |
9,192 |
31,954 |
187,969 |
| Cohen Joshua B | Co-Chief Executive Officer |
Mar 31 '25 |
Sale |
3.47 |
21,490 |
74,482 |
3,355,280 |
| Klee Justin B. | Co-Chief Executive Officer |
Mar 31 '25 |
Sale |
3.46 |
21,490 |
74,454 |
3,355,276 |
| Zeiher Bernhardt G | Director |
Mar 20 '25 |
Buy |
3.70 |
10,000 |
37,005 |
10,000 |
| Klee Justin B. | Co-Chief Executive Officer |
Mar 03 '25 |
Sale |
3.15 |
4,595 |
14,483 |
3,196,648 |
| Cohen Joshua B | Co-Chief Executive Officer |
Mar 03 '25 |
Sale |
3.17 |
4,595 |
14,549 |
3,196,652 |
| Mazzariello Gina | Chief Legal Officer |
Mar 03 '25 |
Sale |
3.12 |
1,611 |
5,022 |
133,310 |
| Mazzariello Gina | Chief Legal Officer |
Feb 24 '25 |
Sale |
3.15 |
4,169 |
13,145 |
134,921 |
| Klee Justin B. | Co-Chief Executive Officer |
Feb 05 '25 |
Option Exercise |
1.57 |
36,310 |
57,007 |
3,201,243 |
0.91%
3.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):